Sandoz Pushes Back On AMR And ‘Dysfunctional’ Antibiotics Market
Get Access Balance Right And Consider Market Reforms, Urge Senior Executives
Sandoz CEO Richard Saynor and global head of anti-infectives Ian Ball have spoken out on the threat of antimicrobial resistance and the “increasing dysfunctionality” of the market framework for antibiotics.
You may also be interested in...
To increase manufacturing capacity for finished dosage form penicillins, Sandoz is investing another €50m into its key antibiotics site in Kundl, Austria. But the company feels that fundamental reforms are needed from regulators to ensure the long-term sustainability of European-based antibiotic manufacturing and supply.
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.